ReviewiScience2026
Progress in siRNA therapy and delivery platforms for osteoarthritis.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is driven by a cycle of cartilage decay, synovial inflammation, and bone remodeling. This progression is fueled by the self-perpetuating synergy between matrix-degrading enzymes and pro-inflammatory cytokines, posing a formidable barrier to effective therapy. Small interfering RNAs (siRNAs) offer a transformative precision medicine paradigm, harnessing the RNA interference (RNAi) machinery to silence pathogenic drivers. However, their clinical application hinges on navigating the complex intra-articular microenvironment. This review synthesizes current progress in siRNA delivery architectures, spanning viral vectors, lipidic nanoplatforms, polymeric assemblies, and hybrid biomimetic systems. The spatiotemporal retention and intracellular bioavailability of siRNAs have been augmented by key engineering breakthroughs, including ligand-mediated active targeting, precise surface topography tuning, and integrated stimulus-responsive functionalities. This review, by exploring future directions like multi-target silencing and the use of large animal models relevant to clinical practice, highlights how siRNA-based treatments are moving beyond experimental ideas to applications as real anti-OA drugs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.